Trastuzumab botidotin clinical trials
Also written A166.
How each study uses trastuzumab botidotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trastuzumab botidotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- A166
- 4
Studies by the year they started
4 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2023 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (3) · Klus Pharma Inc. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test trastuzumab botidotin, phase 3 first.
- Nov 2026A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyPhase 3 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Sep 2027A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerPhase 2 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Studies
Open first, then newest update. How each study uses trastuzumab botidotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast CancerRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07299825Written as A166
- A Study of A166 in Patients With Advanced Solid Malignant TumorsCompletedPhase 1Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT05311397Written as A166
- A Study of A166 Versus Trastuzumab Emtansine (T-DM1) in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane TherapyActive, not recruitingPhase 3Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT06968585Written as A166
- Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneCompletedPhase 1/2Klus Pharma Inc.NCT03602079Written as A166
Codes
What other systems call trastuzumab botidotin · ClinicalTrials.gg INT015277
- UNII (FDA) 6HUZ008AZXTRASTUZUMAB BOTIDOTINOne source FDA
- NCI Thesaurus C156480Trastuzumab BotidotinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6HUZ008AZX | TRASTUZUMAB BOTIDOTIN | One source FDA |
| NCI Thesaurus | C156480 | Trastuzumab Botidotin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.